XenaCare Holdings has announced that it has become a national sponsor of the Arthritis Foundation, one of the largest nonprofit organizations dedicated to arthritis research and public health education.
Delray Beach, FL. – November 27, 2009 – XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that is has become a national sponsor of the Arthritis Foundation at the National Proud Sponsor level.
“As one of the largest and most well-respected nonprofit organizations dedicated to arthritis research and public health education, the Arthritis Foundation is on an important mission to improve the quality of life for millions of people around the world suffering from more than 100 different types of arthritis,” explained Frank Rizzo, President of XenaCare Holdings. “We are honored to be associated with the Arthritis Foundation as a national sponsor and we look forward to continuing to work closely with the Organization to help support their ongoing efforts,” he added.
With the sponsorship of the Arthritis Foundation, Cobroxin may bear the Arthritis Foundation Proud Sponsor Logo on its packaging. This logo illustrates to consumers that Cobroxin is proud to support the Arthritis Foundation's efforts to help people take control of arthritis. Additionally, the Arthritis Foundation will work with XenaCare and other Proud Sponsors to help build awareness about Cobroxin through its magazine, Arthritis Today, its membership e-newsletter and on its website, Arthritis.org.
The National Proud Sponsor program represents the highest level of collaboration with the Arthritis Foundation. According to the Arthritis Foundation, Proud Sponsors provide critical support of the Foundation's key mission areas including:
• Advocacy - Local, state and national efforts to advance vital legislation.
• Research - Cutting edge, peer-reviewed research that has the greatest potential for advancement in the search for a cure.
• Public health - Information and empowering programs and services.
• Community-based outreach - Network of 42 chapter offices
Additional National Proud Sponsors include Wyeth, Abbott, Nature Made® TripleFlex™, Genentech, Bristol-Myers Squibb and Osteo Bi-Flex.
In 2009, XenaCare received the exclusive license from biotechnology company, Nutra Pharma Corporation (OTCBB: NPHC), to market and distribute Cobroxin throughout the United States. Cobroxin is clinically proven to treat moderate to severe (Stage 2) chronic pain and is currently available for sale at several retailers, including online at Cobroxin.com.
About XenaCare HoldingsXenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In 2009, the Company received the exclusive license to market and distribute Cobroxin within the United States. Cobroxin is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation that is clinically proven to treat moderate to severe (Stage 2) pain. The drug, which recently won the award for “Best New Product” at the Efficient Collaborative Retail Marketing (ECRM) Conference held in Miami, Florida, is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating repetitive stress, arthritis, and joint pain.
Benefits to Cobroxin include:
• All Natural
• Non-Addictive
• Non-Narcotic
• Non-Opiate
• More Potent than Morphine
• Long Lasting
The Company’s additional clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body’s oxygen carrying capacities designed to support digestion. The Company also offers formulations for the lifestyle performance market, which consists of sports line for athletes, including the SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays.
http://www.Nutrapharma.com
http://www.Cobroxin.com
Kevin McKnight
800-404-8982
Undiscovered Equities, Inc.
101 Plaza Real South, Suite 212
Boca Raton, FL 33432
www.undiscoveredequities.com
Friday, November 27, 2009
Monday, November 23, 2009
Manas (OTCBB: MNAP) Enters Into Letter of Intent to Sell A Portion of Its Interest in Its Albanian Project
BAAR, SWITZERLAND, November 23rd, 2009.
Manas Petroleum (“Manas”) (OTCBB: MNAP) is pleased to report that it has entered into an arm’s length binding letter of intent (the "LOI") dated November 19, 2009 with WWI Resources ("WWI") a TSX-V listed company, pursuant to which Manas will sell all of the shares of one of its wholly-owned subsidiaries (the “Subsidiary”) in exchange for a minimum of 100,000,000 common shares and a signing bonus in cash. At or prior to closing, Manas will reorganize its affairs such that the Subsidiary will own 100% of Manas’ Albanian assets. The LOI provides that, after closing, WWI will be obligated to issue to Manas up to an aggregate of 150,000,000 additional WWI common shares upon the achievement of certain operational targets.
Completion of the transaction is subject to, among other things, completion of due diligence satisfactory to both parties, execution of a definitive agreement, receipt of all necessary regulatory and shareholder approvals and completion of a private placement in which WWI will sell 100,000,000 units at a price of $0.25 per unit for gross proceeds of (Cdn) $25,000,000. Each unit will consist of one common share and one warrant, with each warrant entitling the holder to purchase a further common share at a price of (Cdn) $ 0.45 per share for a period of 5 years from closing. At closing, each of WWI and Manas will appoint 3 directors to the board of WWI and the current officers of Manas will be appointed as officers of WWI. At closing, the Subsidiary will hold three Production Sharing Contracts (PSCs) onshore Blocks in Albania that comprise 1.7 million net acres with 100% working interest. The PSCs are for Blocks A, B, D, E and for Blocks 2 & 3. There have been nine large structures identified in Blocks A, B, D & E and three structures on Blocks 2 & 3. It is important to note that Block 2 is within the area where Bankers Petroleum’s (BNK.TO) current shallow oil production derives from. Manas has the right to explore and produce oil from the deeper targets. In 2001, the Shpiragu 1 well was drilled by Occidental petroleum in Block 2. The Shpiragu-1 well averaged 400 -1,200 bbl/d of light oil, confirming an active hydrocarbon system. There are no known reserves on any of these properties.
Eric Herlyn, Chief Executive Officer of Manas Petroleum, comments, “We believe this is an excellent transaction for Manas as it will create significant shareholder value moving forward. This transaction is consistent with Manas’ core strategy of acquiring high impact oil and gas licenses and then limiting the financial burdens and risks associated with the exploration and development.” A more extensive press release will be out shortly which will provide more details of the transaction.
Kevin McKnight1-800-404-8982
Undiscovered Equities, Inc.
101 Plaza Real S, Ste 212
Boca Raton, FL 33432
www.undiscoveredequities.com
Manas Petroleum (“Manas”) (OTCBB: MNAP) is pleased to report that it has entered into an arm’s length binding letter of intent (the "LOI") dated November 19, 2009 with WWI Resources ("WWI") a TSX-V listed company, pursuant to which Manas will sell all of the shares of one of its wholly-owned subsidiaries (the “Subsidiary”) in exchange for a minimum of 100,000,000 common shares and a signing bonus in cash. At or prior to closing, Manas will reorganize its affairs such that the Subsidiary will own 100% of Manas’ Albanian assets. The LOI provides that, after closing, WWI will be obligated to issue to Manas up to an aggregate of 150,000,000 additional WWI common shares upon the achievement of certain operational targets.
Completion of the transaction is subject to, among other things, completion of due diligence satisfactory to both parties, execution of a definitive agreement, receipt of all necessary regulatory and shareholder approvals and completion of a private placement in which WWI will sell 100,000,000 units at a price of $0.25 per unit for gross proceeds of (Cdn) $25,000,000. Each unit will consist of one common share and one warrant, with each warrant entitling the holder to purchase a further common share at a price of (Cdn) $ 0.45 per share for a period of 5 years from closing. At closing, each of WWI and Manas will appoint 3 directors to the board of WWI and the current officers of Manas will be appointed as officers of WWI. At closing, the Subsidiary will hold three Production Sharing Contracts (PSCs) onshore Blocks in Albania that comprise 1.7 million net acres with 100% working interest. The PSCs are for Blocks A, B, D, E and for Blocks 2 & 3. There have been nine large structures identified in Blocks A, B, D & E and three structures on Blocks 2 & 3. It is important to note that Block 2 is within the area where Bankers Petroleum’s (BNK.TO) current shallow oil production derives from. Manas has the right to explore and produce oil from the deeper targets. In 2001, the Shpiragu 1 well was drilled by Occidental petroleum in Block 2. The Shpiragu-1 well averaged 400 -1,200 bbl/d of light oil, confirming an active hydrocarbon system. There are no known reserves on any of these properties.
Eric Herlyn, Chief Executive Officer of Manas Petroleum, comments, “We believe this is an excellent transaction for Manas as it will create significant shareholder value moving forward. This transaction is consistent with Manas’ core strategy of acquiring high impact oil and gas licenses and then limiting the financial burdens and risks associated with the exploration and development.” A more extensive press release will be out shortly which will provide more details of the transaction.
Kevin McKnight1-800-404-8982
Undiscovered Equities, Inc.
101 Plaza Real S, Ste 212
Boca Raton, FL 33432
www.undiscoveredequities.com
Thursday, November 19, 2009
Nutra Pharma Introduces Chronic Pain Reliever, Nyloxin OTC, for International Distribution (OTCBB: NPHC)
Nutra Pharma Introduces Chronic Pain Reliever, Nyloxin OTC, for International Distribution (OTCBB: NPHC)
Nov 19, 2009 - Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today the introduction of Nyloxin OTC for the treatment of chronic pain. Nyloxin OTC (http://www.nyloxin.com/) will be marketed and sold internationally alongside the Company's prescription pain reliever, Nyloxin Rx. "Nyloxin OTC is an important addition to our line of pain relievers and offers many benefits similar to that of Cobroxin, our over-the-counter pain reliever currently being marketed and sold in the United States" explained Dr. Paul Reid, CEO of ReceptoPharm (http://www.receptopharm.com/). "By introducing our pain relievers internationally under a single, unified brand, Nyloxin, we can better leverage our growth overseas as we complete the required registrations and build awareness for both our prescription pain reliever, Nyloxin Rx, as well as our over-the-counter pain reliever, Nyloxin OTC," he added.
Nutra Pharma recently announced its intention to begin the drug registration process for its pain relievers in Canada, Europe, and South America. The Company expects to have these registrations completed in the near term and plans to subsequently launch Nyloxin Rx and Nyloxin OTC in those territories through select international licensees.
"The international pain market represents a significant growth opportunity for our company, especially in countries where there is limited access to opiate-based medicines," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma (http://www.nutrapharma.com/). "With the introduction of Nyloxin OTC, we now believe we can offer a more well-rounded product line that covers a much broader spectrum of the pain management market," he concluded.
Nyloxin OTC, which was developed by Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
About Nutra Pharma Corp. Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.nyloxin.com
http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Cobroxin.com
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Nov 19, 2009 - Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today the introduction of Nyloxin OTC for the treatment of chronic pain. Nyloxin OTC (http://www.nyloxin.com/) will be marketed and sold internationally alongside the Company's prescription pain reliever, Nyloxin Rx. "Nyloxin OTC is an important addition to our line of pain relievers and offers many benefits similar to that of Cobroxin, our over-the-counter pain reliever currently being marketed and sold in the United States" explained Dr. Paul Reid, CEO of ReceptoPharm (http://www.receptopharm.com/). "By introducing our pain relievers internationally under a single, unified brand, Nyloxin, we can better leverage our growth overseas as we complete the required registrations and build awareness for both our prescription pain reliever, Nyloxin Rx, as well as our over-the-counter pain reliever, Nyloxin OTC," he added.
Nutra Pharma recently announced its intention to begin the drug registration process for its pain relievers in Canada, Europe, and South America. The Company expects to have these registrations completed in the near term and plans to subsequently launch Nyloxin Rx and Nyloxin OTC in those territories through select international licensees.
"The international pain market represents a significant growth opportunity for our company, especially in countries where there is limited access to opiate-based medicines," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma (http://www.nutrapharma.com/). "With the introduction of Nyloxin OTC, we now believe we can offer a more well-rounded product line that covers a much broader spectrum of the pain management market," he concluded.
Nyloxin OTC, which was developed by Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
About Nutra Pharma Corp. Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.nyloxin.com
http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Cobroxin.com
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Thursday, November 12, 2009
Houston American Energy Investor Presentation
Company Overview
Houston American Energy Corp (NASDAQ:HUSA), the “Company”, is a growth-oriented independent energy company engaged in the exploration, development and production of crude oil and natural gas resources
Operations focused in Colombia
•Current production of approximately 850 barrels of oil equivalent per day•Participated in drilling of 100 wells in Colombia to date•Developing new international projects with a focus on Colombia, Peru and Brazil
Significant concessions in Colombia with substantial drilling inventory identified by advanced 3-D seismic interpretation
•Over 895,000 gross acres with more than 100 currently identified drilling prospects
Investment Opportunity
Unique portfolio of high impact, large reserve potential projects in Colombia•Pure-play small cap oil focused investment opportunity with substantial upside potential•Significant acreage position focused in the Llanos Basin in Colombia•Favorable government royalties and fiscal terms on existing contracts
Significant Technical Partner with SK Energy, a leading Asian integrated oil and gas company
Proven Track Record
•Participating in successful drilling program led by Hupecol•Drilled 100 wells in Colombia with a 70% success rate to date•With approximately $19.8MM in invested capital management has generated in excess of $112.0MM of market capital to date
Low cost structure•Non-operator strategy allows for minimal corporate staff•Colombian properties have lower finding and development costs versus U.S. conventional and unconventional reserves
Experienced management and board of directors with access to proprietary deal flow
Simple capitalization structure
Business Strategy
Explore and develop existing properties through the drill bit•Increase production and cash flow by drilling and completing identified well locations•Quantify value of our asset base through an aggressive testing and drilling program•Explore for and develop additional proved reserves on approximately 150,000 net acres
Acquire additional interest in oil and gas properties through partnerships and joint ventures with experienced operators•Target acquisitions that enhance our core areas•Focus on high impact, lower risk drilling prospects
Capitalize on the expertise, experience and strategic relationships of the management team and board of directors
For a full presentation on Houston American Energy Group click here
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Houston American Energy Corp (NASDAQ:HUSA), the “Company”, is a growth-oriented independent energy company engaged in the exploration, development and production of crude oil and natural gas resources
Operations focused in Colombia
•Current production of approximately 850 barrels of oil equivalent per day•Participated in drilling of 100 wells in Colombia to date•Developing new international projects with a focus on Colombia, Peru and Brazil
Significant concessions in Colombia with substantial drilling inventory identified by advanced 3-D seismic interpretation
•Over 895,000 gross acres with more than 100 currently identified drilling prospects
Investment Opportunity
Unique portfolio of high impact, large reserve potential projects in Colombia•Pure-play small cap oil focused investment opportunity with substantial upside potential•Significant acreage position focused in the Llanos Basin in Colombia•Favorable government royalties and fiscal terms on existing contracts
Significant Technical Partner with SK Energy, a leading Asian integrated oil and gas company
Proven Track Record
•Participating in successful drilling program led by Hupecol•Drilled 100 wells in Colombia with a 70% success rate to date•With approximately $19.8MM in invested capital management has generated in excess of $112.0MM of market capital to date
Low cost structure•Non-operator strategy allows for minimal corporate staff•Colombian properties have lower finding and development costs versus U.S. conventional and unconventional reserves
Experienced management and board of directors with access to proprietary deal flow
Simple capitalization structure
Business Strategy
Explore and develop existing properties through the drill bit•Increase production and cash flow by drilling and completing identified well locations•Quantify value of our asset base through an aggressive testing and drilling program•Explore for and develop additional proved reserves on approximately 150,000 net acres
Acquire additional interest in oil and gas properties through partnerships and joint ventures with experienced operators•Target acquisitions that enhance our core areas•Focus on high impact, lower risk drilling prospects
Capitalize on the expertise, experience and strategic relationships of the management team and board of directors
For a full presentation on Houston American Energy Group click here
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever
Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain RelieverNutra Pharma has announced its intention to begin the drug registration process in Brazil and Colombia for its over-the-counter pain reliever. The company is currently marketing a similar analgesic, Cobroxin, in the United States for the treatment of moderate to severe (Stage 2) chronic pain.
Press Release Source: Nutra Pharma Corp. On 9:03 am EST, Thursday November 12, 2009PLANTATION, Fla.--Nutra Pharma Corp. (OTCBB: NPHC - News), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Brazil and Colombia for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.
“Beginning the drug registration process in Brazil and Colombia offers us the opportunity to introduce our over-the-counter pain reliever into countries that have significant portions of their populations suffering from chronic pain, but lack sufficient access to opioid-based analgesics,” explained Dr. Paul Reid, CEO of ReceptoPharm. “We have already begun conversations with potential South American licensees and plan to initiate the drug registration process in both countries as we move into 2010,” he added.
Nutra Pharma introduced a similar pain medicine in the United States in August under the brand Cobroxin. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, is currently available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
“We are excited to begin the drug registration process in Brazil and Colombia, as these two countries make up approximately 60% of the population of South America and represent the most important entry-points for launching our pain reliever into the entire South American market,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma. “While we complete our drug registration in Brazil and Colombia, we plan to continue building our international presence by registering our pain drug in additional countries worldwide,” he concluded.
In September, Nutra Pharma announced its intention to begin drug registration for its pain reliever in Canada and Europe. Given the existing regulatory requirements in these territories, the Company expects to complete these registrations in the near-term.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Cobroxin.com
Kevin McKnight
1-800-404-8982
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Press Release Source: Nutra Pharma Corp. On 9:03 am EST, Thursday November 12, 2009PLANTATION, Fla.--Nutra Pharma Corp. (OTCBB: NPHC - News), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Brazil and Colombia for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.
“Beginning the drug registration process in Brazil and Colombia offers us the opportunity to introduce our over-the-counter pain reliever into countries that have significant portions of their populations suffering from chronic pain, but lack sufficient access to opioid-based analgesics,” explained Dr. Paul Reid, CEO of ReceptoPharm. “We have already begun conversations with potential South American licensees and plan to initiate the drug registration process in both countries as we move into 2010,” he added.
Nutra Pharma introduced a similar pain medicine in the United States in August under the brand Cobroxin. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, is currently available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
“We are excited to begin the drug registration process in Brazil and Colombia, as these two countries make up approximately 60% of the population of South America and represent the most important entry-points for launching our pain reliever into the entire South American market,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma. “While we complete our drug registration in Brazil and Colombia, we plan to continue building our international presence by registering our pain drug in additional countries worldwide,” he concluded.
In September, Nutra Pharma announced its intention to begin drug registration for its pain reliever in Canada and Europe. Given the existing regulatory requirements in these territories, the Company expects to complete these registrations in the near-term.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Cobroxin.com
Kevin McKnight
1-800-404-8982
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Monday, November 9, 2009
HOUSTON AMERICAN ENERGY (Nasdaq: HUSA) ANNOUNCES THIRD QUARTER 2009 FINANCIAL RESULTS -- Company Declares Quarterly Dividend of $.005 per Share
Houston, Texas - November 6, 2009 - Houston American Energy Corp. (Nasdaq: HUSA) yesterday reported its financial results for the quarter ended September 30, 2009.
The Company reported net income for the three months ended September 30, 2009 of $428,578, or $0.02 per share, on revenues of $2,403,996, as compared to net income of $798,832, or $0.03 per share, on revenues of $2,350,782 for the three months ended September 30, 2008. For the nine months ended September 30, 2009, the company reported a loss of $937,634, or $0.03 per share, on revenue of $3,983,256, as compared to net income of $4,870,356, or $0.17 per diluted share, on revenues of $8,616,868. The increase in revenue for the quarter was primarily attributable to increased volumes in our Colombia operations, offset by decreased commodity prices realized in the 2009 quarter as compared to 2008. The decrease in revenue for the nine months ended September 30, 2009 was primarily attributable to reduced production from the majority of our wells being shut in during the later half of the 1st quarter and early in the 2nd quarter of 2009, and lost production related to the sale of the Caracara concession in 2008. Mr. John F. Terwilliger, President and Chairman of Houston American Energy, stated, Houston American Energy's production volumes sold in the third quarter showed an 80% improvement over the second quarter and a 46% improvement versus the volumes sold during the third quarter of 2008. We expect this trend to continue into the fourth quarter as production volumes have been strong and are expected to stay strong going forward. The next six months should be very eventful for Houston American Energy as we expect to commence drilling on one of our new blocks in Colombia. In addition, during this period we should have the results of the sales process of a portion of our Colombian assets as described in our Form 8-K filed on September 23, 2009, which we believe will provide significant additional liquidity to the Company. These are exciting times for Houston American Energy as we are embarking on a new and potentially very significant growth phase for the Company.
In view of the Board of Directors' confidence in the outlook for Houston American Energy, a dividend of $0.005 per share has been declared for shareholders of record as of December 1, 2009 with a payment date of December 17, 2009.
About Houston American Energy Corp.
Based in Houston, Texas, Houston American Energy Corp. is an independent energy company with interests in oil and natural gas wells and prospects. The company's business strategy includes a property mix of producing and non-producing assets with a focus on Texas, Louisiana and Colombia. Additional information can be accessed by reviewing our Form 10-Q and other periodic reports filed with the Securities and Exchange Commission which can be found on our website at www.houstonamericanenergy.com.
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
disclaimer
The Company reported net income for the three months ended September 30, 2009 of $428,578, or $0.02 per share, on revenues of $2,403,996, as compared to net income of $798,832, or $0.03 per share, on revenues of $2,350,782 for the three months ended September 30, 2008. For the nine months ended September 30, 2009, the company reported a loss of $937,634, or $0.03 per share, on revenue of $3,983,256, as compared to net income of $4,870,356, or $0.17 per diluted share, on revenues of $8,616,868. The increase in revenue for the quarter was primarily attributable to increased volumes in our Colombia operations, offset by decreased commodity prices realized in the 2009 quarter as compared to 2008. The decrease in revenue for the nine months ended September 30, 2009 was primarily attributable to reduced production from the majority of our wells being shut in during the later half of the 1st quarter and early in the 2nd quarter of 2009, and lost production related to the sale of the Caracara concession in 2008. Mr. John F. Terwilliger, President and Chairman of Houston American Energy, stated, Houston American Energy's production volumes sold in the third quarter showed an 80% improvement over the second quarter and a 46% improvement versus the volumes sold during the third quarter of 2008. We expect this trend to continue into the fourth quarter as production volumes have been strong and are expected to stay strong going forward. The next six months should be very eventful for Houston American Energy as we expect to commence drilling on one of our new blocks in Colombia. In addition, during this period we should have the results of the sales process of a portion of our Colombian assets as described in our Form 8-K filed on September 23, 2009, which we believe will provide significant additional liquidity to the Company. These are exciting times for Houston American Energy as we are embarking on a new and potentially very significant growth phase for the Company.
In view of the Board of Directors' confidence in the outlook for Houston American Energy, a dividend of $0.005 per share has been declared for shareholders of record as of December 1, 2009 with a payment date of December 17, 2009.
About Houston American Energy Corp.
Based in Houston, Texas, Houston American Energy Corp. is an independent energy company with interests in oil and natural gas wells and prospects. The company's business strategy includes a property mix of producing and non-producing assets with a focus on Texas, Louisiana and Colombia. Additional information can be accessed by reviewing our Form 10-Q and other periodic reports filed with the Securities and Exchange Commission which can be found on our website at www.houstonamericanenergy.com.
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
disclaimer
Wednesday, November 4, 2009
Nutra Pharma's (OTCBB: NPHC) Cobroxin Distributor, XenaCare Holdings Announces Availability of Cobroxin through the Chain Drug Marketing Association
XenaCare Holdings (OTCBB: XCHO) has Announced That the Chain Drug Marketing Association (CDMA) Will Begin Taking Inventory of Cobroxin for Redistribution and Sale Through its 6,000 Member Pharmacies
DELRAY BEACH, Fla., Nov 04, 2009 - XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that the Chain Drug Marketing Association (CDMA) will begin inventorying Cobroxin for redistribution to its member pharmacies. The CDMA currently has over 6,000 independent pharmacy members throughout the United States. "As one of the largest pharmacy organizations in the United States, we are excited to be working with the CDMA to distribute Cobroxin to its independent pharmacy members," explained Frank Rizzo, President of XenaCare Holdings. "Having a presence in CDMA member pharmacies will help us build significant awareness about Cobroxin as we continue to expand the brand nationwide through retailers and our multimillion dollar national advertising campaign," he concluded.
Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
Additional benefits to Cobroxin include:
-- All Natural
-- Non-Addictive
-- Non-Narcotic
-- Non-Opiate
-- More Potent than Morphine
-- Long Lasting
XenaCare Holdings, which holds the exclusive license from Nutra Pharma Corporation (OTCBB: NPHC) to market and distribute Cobroxin in the United States, announced in October that it had begun accepting orders for Cobroxin online at Cobroxin.com. Additionally, the Company has recently begun distribution to online and brick-and-mortar retailers and will continue to announce locations where Cobroxin will be available for sale.
About Nutra Pharma:
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.cobroxin.com/
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
http://www.undiscoveredequities.com/
DELRAY BEACH, Fla., Nov 04, 2009 - XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that the Chain Drug Marketing Association (CDMA) will begin inventorying Cobroxin for redistribution to its member pharmacies. The CDMA currently has over 6,000 independent pharmacy members throughout the United States. "As one of the largest pharmacy organizations in the United States, we are excited to be working with the CDMA to distribute Cobroxin to its independent pharmacy members," explained Frank Rizzo, President of XenaCare Holdings. "Having a presence in CDMA member pharmacies will help us build significant awareness about Cobroxin as we continue to expand the brand nationwide through retailers and our multimillion dollar national advertising campaign," he concluded.
Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
Additional benefits to Cobroxin include:
-- All Natural
-- Non-Addictive
-- Non-Narcotic
-- Non-Opiate
-- More Potent than Morphine
-- Long Lasting
XenaCare Holdings, which holds the exclusive license from Nutra Pharma Corporation (OTCBB: NPHC) to market and distribute Cobroxin in the United States, announced in October that it had begun accepting orders for Cobroxin online at Cobroxin.com. Additionally, the Company has recently begun distribution to online and brick-and-mortar retailers and will continue to announce locations where Cobroxin will be available for sale.
About Nutra Pharma:
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.cobroxin.com/
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
http://www.undiscoveredequities.com/
Monday, November 2, 2009
Nutra Pharma (OTCBB: NPHC) featured company in Wall Street Transcript
Nutra Pharma (OTCBB: NPHC) featured company in Wall Street Transcript
Rik Deitsch, President, CEO and Director of Nutra Pharma (NPHC) talked to The Wall Street Transcript about his company Nutra Pharma. Click here to read the complete interview.
For the full article please click here: http://www.twst.com/pdf/ANG600.pdf
Company Profile:
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Rik Deitsch, President, CEO and Director of Nutra Pharma (NPHC) talked to The Wall Street Transcript about his company Nutra Pharma. Click here to read the complete interview.
For the full article please click here: http://www.twst.com/pdf/ANG600.pdf
Company Profile:
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
1515 S Federal Hwy, Ste 207
Boca Raton, FL 33432
www.undiscoveredequities.com
Subscribe to:
Posts (Atom)